Trial sponsors have shared these lung cancer clinical trials that are enrolling participants to help advance lung cancer science. Most medications and treatments currently available are thanks to patients who went through clinical trials to prove the effectiveness and safety of the treatment being studied.

Clinical trials have eligibility requirements to join so that participants remain safe, while having a likelihood of success when it comes to treatment.

If you’re interested in joining one of the clinical trials below, make sure to talk with your doctor and ask if they think it would be helpful for your treatment. Some patients may have additional health problems that could be made worse by treatments used in a clinical trial.

Note: The status of each trial may change with time. Please reach out to the contact listed in each trial opportunity to get the most up-to-date information. 

Available Clinical Trials

HER2 NSCLC - sevabertinib

Study to Learn How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared to Standard Treatment, in People Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Contact:

Phone Number: (+)1-888-84 22937 
Email: [email protected]

About the trial:

This is a study to learn more about how well sevabertinib works and how safe it is compared with standard treatment. If patients pass the screening phase, they will receive either sevabertinib (study drug) or chemo immunotherapy (standard of care). 

Who can participate:

The following are a few requirements patients should have in order to participate in the study: 

  1. Documented diagnosis of advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations
  2. No previous treatment for this specific diagnosis 
  3. Ability to swallow oral medication and comply with study requirements

Learn More

NSCLC - ivonescimab + chemotherapy

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Contact:

[email protected]

About the trial:

This is a randomized, Phase 3 global study evaluating ivonescimab plus chemotherapy compared to pembrolizumab plus chemotherapy in patients with metastatic NSCLC who have not received any previous treatment. 

Who can participate?

The study is open to patients with non-squamous and squamous non-small cell lung cancer, regardless of PD-L1 score. HARMONi-3 is evaluating both overall survival (OS) as well as progression-free survival (PFS).

Learn More

SCLC - study drug IDE849

Phase 1/2 multicenter, clinical study of IDE849 in patients with small cell lung cancer (SCLC)

Contact:

[email protected]

About the trial:

The purpose of this study is to assess how safe, tolerable, and effective the study drug, IDE849, is in SCLC. Early studies suggest IDE849 may demonstrate manageable safety and encouraging antitumor activity.

Who can participate?

Patients may be eligible to participate if they have SCLC that has progressed or has returned after previous standard treatment.

Learn More

NSCLC - tumor treating fields

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Contact:

Donald Carlino
[email protected]

About the trial:

This clinical study is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) delivered by the NovoTTF-200T device together with standard immunotherapy, pembrolizumab and platinum-based chemotherapy, compared to pembrolizumab and platinum-based chemotherapy alone for first line treatment of patients with metastatic NSCLC.

Who can participate:

The LUNAR-2 study is intended for patients who have been diagnosed with, but have not been treated for, metastatic non-small cell lung cancer (NSCLC). To be eligible* for this study, you must be at least 18 (22 in the US) years of age, be diagnosed with stage 4 NSCLC, and have not received prior treatments for metastatic NSCLC.

*Not a complete list of eligibility requirements.

Learn More

*These trials are listed for a period of 3 months.